ACUT:OTC-Accustem Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.35

Change

-0.02 (-5.41)%

Market Cap

USD 4.14M

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJY UCB SA ADR

N/A

USD 24.49B
UCBJF UCB SA

N/A

USD 23.19B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.52B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.10B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing ACUT

DESE:LSE 1.22 % 0.00 %

N/A

N/A
WTEC:F 1.22 % 0.00 %

N/A

N/A
WTEC:XETRA 1.22 % 0.00 %

N/A

N/A
DESD:LSE 0.90 % 0.00 %

N/A

N/A
EQLT 0.45 % 0.75 %

N/A

N/A
SMD 0.42 % 0.10 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.06% 19% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.06% 20% F 9% A-
Trailing 12 Months  
Capital Gain -64.88% 29% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.88% 29% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.75% 57% F 58% F
Dividend Return 10.75% 57% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.99% 60% D- 45% F
Risk Adjusted Return 18.86% 67% D+ 54% F
Market Capitalization 4.14M 42% F 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.